A consistent lack of a significant decrease in the BCL-XL transcript level in melanoma cells exposed to 17-aminogeldanamycin might be explained by different NF-κB dimer compositions required for the activation of BCL2L1 expression. The gene discussed is BCL2L1; the disease is melanoma.